Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, UK.
Mol Pharm. 2012 Mar 5;9(3):563-9. doi: 10.1021/mp200415g. Epub 2012 Feb 10.
Determining bioequivalence for solution pressurized metered dose inhalers (pMDI) is difficult because the critical characteristics of such products are poorly defined. The aim of this study was to elucidate the non-aerodynamic properties of the emitted aerosol particles from two solution pMDI products that determine their biopharmaceutical differences after deposition. Novel particle capture and analysis techniques were employed to characterize the physicochemical and biopharmaceutical properties of two beclomethasone dipropionate (BDP) products: QVAR and Sanasthmax. The BDP particles emitted from the Sanasthmax inhaler were discernibly different those emitted from QVAR in terms of size (50% larger, less porous), solid state (less crystalline) and dissolution (20-fold slower). When deposited onto the surface of respiratory epithelial cell layers, QVAR delivered ∼50% more BDP across the cell layer in 60 min than Sanasthmax. Biopharmaceutical performance was not attributable to individual particle properties as these were manifold with summative and/or competing effects. The cell culture dissolution-absorption model revealed the net effect of the particle formed on drug disposition and was predictive of human systemic absorption of BDP delivered by the test inhalers. This illustrates the potential of the technique to detect the effect of formulation on the performance of aerosolized particles and contribute to assessment of bioequivalence.
确定溶液型定量吸入气雾剂(pMDI)的生物等效性具有一定难度,因为此类产品的关键特性尚未明确界定。本研究旨在阐明两种溶液型 pMDI 产品的非空气动力学气溶胶颗粒特性,这些特性决定了产品在沉积后的生物药剂学差异。本研究采用新型颗粒捕获和分析技术,对两种丙酸倍氯米松(BDP)产品(QVAR 和 Sanasthmax)的理化和生物药剂学性质进行了表征。从 Sanasthmax 吸入器中释放出的 BDP 颗粒在大小(大 50%,更疏松)、固体状态(结晶度更低)和溶解速度(慢 20 倍)方面,与 QVAR 明显不同。当沉积在呼吸道上皮细胞层表面时,QVAR 在 60 分钟内穿过细胞层的 BDP 量比 Sanasthmax 多约 50%。生物药剂学性能与个别颗粒特性无关,因为这些特性具有累积和/或竞争效应。细胞培养溶解-吸收模型揭示了颗粒形成对药物分布的净效应,并可预测试验吸入器中 BDP 的人体全身吸收。这说明了该技术具有检测制剂对雾化颗粒性能影响的潜力,并有助于评估生物等效性。